Welcome to our dedicated page for Madrigal Pharmac SEC filings (Ticker: MDGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decipher a 300-page biopharma filing packed with clinical endpoints and FDA jargon can stall even seasoned analysts. Madrigal Pharmaceuticals’ SEC documents are no exception: every 10-K details Rezdiffra’s trial design, while 8-Ks flag pivotal data releases that can move the stock overnight. If you have searched for “Madrigal Pharmaceuticals SEC filings explained simply,” you know the challenge.
Stock Titan cuts through that complexity. Our AI reads each Madrigal Pharmaceuticals quarterly earnings report 10-Q filing, highlights cash-runway updates, and links them to ongoing MAESTRO studies. Need fast context on a sudden press release? We deliver Madrigal Pharmaceuticals 8-K material events explained in plain English within minutes of EDGAR posting. Real-time alerts surface Madrigal Pharmaceuticals Form 4 insider transactions, so you can follow executive stock trades ahead of regulatory milestones. You will also find the annual report—Madrigal Pharmaceuticals annual report 10-K simplified—and an easy path to the Madrigal Pharmaceuticals proxy statement executive compensation that breaks down R&D-driven pay packages.
Whether you are monitoring Madrigal Pharmaceuticals insider trading Form 4 transactions, comparing Phase 3 expenses line-by-line, or seeking a concise Madrigal Pharmaceuticals earnings report filing analysis, our platform equips you to act decisively. AI-powered summaries, expert tagging, and comprehensive coverage of every form—10-K, 10-Q, 8-K, S-3, plus Madrigal Pharmaceuticals executive stock transactions Form 4 in real time—mean fewer hours lost and more insights gained. Start understanding Madrigal Pharmaceuticals SEC documents with AI instead of wrestling with them.
Madrigal Pharmaceuticals, Inc. (MDGL) Form 144 reports a proposed sale of 3,200 common shares through Morgan Stanley Smith Barney LLC on 08/11/2025 for an aggregate market value of $1,106,336.00. The filing shows 22,289,014 shares outstanding and lists NASDAQ as the exchange.
The shares were acquired on 08/11/2025 by exercise of stock options from the issuer, paid in cash. The filing also discloses multiple recent 10b5-1 sales by Rebecca Taub and Paul A. Friedman during July 2025 totaling 60,377 shares with combined gross proceeds of about $21.3 million.
Madrigal Pharmaceuticals’ Q2-25 10-Q shows the company’s first full quarter of Rezdiffra commercialization driving a dramatic top-line inflection. Net product revenue reached $212.8 m for the quarter and $350.1 m YTD, versus $14.6 m in the prior-year periods. Cost of sales was only $13.6 m YTD, yielding a gross margin above 96%, but heavy commercial scale-up spending pushed operating expenses to $476.6 m (up 45% YoY). Consequently, the H1 operating loss narrowed to $126.5 m from $314.6 m, with a GAAP net loss of $115.5 m (-$5.22/sh).
Cash, cash equivalents and marketable securities totalled $802.0 m at 30 Jun 25, down modestly from $931.3 m at year-end after $136 m operating cash burn and $212 m net investment inflow. Inventory rose to $63.5 m as launch stock builds. Accounts receivable increased to $79.2 m, and gross-to-net reserves expanded to $52.3 m, reflecting payer rebates and copay assistance.
Liabilities were $319.4 m, including $118.4 m outstanding on the Hercules loan. Post-quarter, Madrigal replaced this facility with a new $350 m initial draw (up to $500 m total) Blue Owl secured term loan maturing 2030, subject to a $100 m minimum cash covenant.
22.29 m shares were outstanding on 1 Aug 25. Management emphasises ongoing U.S. launch execution, EU regulatory progress, and outcome trials needed for full Rezdiffra approval and label expansion.
Kenneth Bate, Director at Madrigal Pharmaceuticals (MDGL), reported two significant equity transactions on June 20, 2025:
- Received 715 restricted stock units (RSUs) at $0, bringing total direct common stock ownership to 2,627 shares
- Granted stock options to purchase 1,290 shares at an exercise price of $285.73 per share
Both the RSUs and stock options are scheduled to vest at the company's 2026 annual stockholder meeting, contingent on Bate's continued service as director. The stock options have a ten-year term, expiring on June 20, 2035. The transactions were reported via Form 4 filing, with Mardi Dier signing as attorney-in-fact on June 24, 2025.
Madrigal Pharmaceuticals (MDGL) filed a Form 4 disclosing new equity awards to director Richard S. Levy dated 06/20/2025.
- Levy received 715 restricted stock units (coded “A”) at no cost. The RSUs vest on the date of the 2026 annual meeting, conditional on his continued service.
- He was also granted 1,290 stock options with a $285.73 exercise price and a 06/20/2035 expiration. These options vest 100 % at the 2026 annual meeting, subject to the same service requirement.
Following the transactions, Levy directly owns 21,197 common shares and 1,290 options. No open-market purchases or sales were reported.
Madrigal Pharmaceuticals director Jacqualyn A. Fouse received new equity compensation grants on June 20, 2025, consisting of:
- 203 restricted stock units (RSUs) with a $0 exercise price, bringing total direct common stock ownership to 1,097 shares
- 366 stock options with an exercise price of $285.73 per share
Both the RSUs and stock options are scheduled to vest at the company's 2026 annual stockholder meeting, contingent on continued service as director. The stock options expire on June 20, 2035. This Form 4 filing, signed by attorney-in-fact Mardi Dier, represents standard board of director equity compensation and demonstrates continued alignment of director interests with shareholders through equity ownership.
FAQ
What is the current stock price of Madrigal Pharmac (MDGL)?
What is the market cap of Madrigal Pharmac (MDGL)?
